BRKM5 is one of the week's most dramatic single-stock stories in Latin America — a 29% surge in a single session, driven by a news catalyst that has fundamentally changed the risk picture for Brazil's largest petrochemicals group.
The move came on May 12, as Bloomberg reported that Braskem Idesa — the Mexican joint venture that had become a persistent overhang on the stock — was nearing a deal with creditors on a bankruptcy loan. The stock had already climbed roughly 26% over the prior month, but this week's leg was the decisive step. From R$9.34 at the start of the week to R$11.87 by Tuesday's close, the price is now pressing against the analyst consensus target of R$11.54 — essentially erasing the upside that the Street had penciled in. With earnings also arriving on May 13, the week has stacked catalyst upon catalyst.
The borrow market tells a pointed story about how the setup changed. Cost to borrow reached 16.3% as of May 8 — an elevated level by any standard, and a fraction of the 49.2% peak seen in March 2026, when the Braskem Idesa situation was at its most acute. What's striking is the longer-term arc: CTB was below 1% as recently as late 2024, climbed into the 20-50% range in early-to-mid March 2026 as distress fears intensified, pulled back partially, and has now re-inflated to 16% — reflecting residual demand to borrow even as some short sellers apparently exited. Short interest itself is negligible at 0.001% of free float, down sharply from a brief spike to 0.073% in early May. This is not a short-squeeze story. It is a repricing of distress risk.
The valuation reset reflects that repricing directly. The EV/EBITDA multiple climbed to 9.6x, up roughly 0.3x over both the past week and month as the equity rallied. The P/E has moved dramatically — the implied earnings yield (EP) of 0.15 corresponds to a trailing P/E around 6.5x, compressed from much higher implied multiples when the stock was depressed. The price-to-book is negative at -1.1x, a legacy of accumulated losses that the market is evidently now willing to look through given improving cash generation. EPS surprise ranks in the 96th percentile, a signal that Braskem has been consistently beating lowered expectations. The forward EPS trajectory also improved, with the 12-month forward YoY increase factor scoring in the 82nd percentile.
The ownership structure adds important context. Two shareholders control more than 74% of the company: Kieppe Participações (38.3%) and PETR4 (36.2%), the latter being Petrobras. Neither moved their positions in the most recent reporting. Among international holders, Norges Bank trimmed 3.5 million shares as of early March, while Vanguard added 690,800 shares through end-March and BlackRock added 453,000 through end-April. The direction from international passive and active managers has been mildly positive, though the scale is small against the concentrated Brazilian control. This week's earnings release will be the first major test of whether that control bloc's restructuring narrative holds up under quarterly scrutiny.
The ORTEX short score nudged higher to 33.3 from roughly 24.9 on May 4 — the jump occurred on May 8, the same day CTB data was last captured. This is consistent with a brief re-engagement from short sellers ahead of the catalyst, rather than a sustained build. The score has previously spiked as high as 39.5 in mid-March, coinciding with the peak CTB episode. That it is rising modestly again, even as the stock surges, suggests a subset of participants is positioning for the possibility that the Idesa deal optimism runs ahead of the fundamentals in the earnings print.
The earnings history is worth noting here. The April 29 event produced a 1-day gain of 8% and a 5-day gain of 11.6%. The April 27 event saw a 1-day loss of 1.3% but a 5-day gain of 10.7%. The March 27 event was more severe: a 1-day fall of 11.3% and a 5-day loss of 17.2%. With the stock already up 29% on the day of the May 13 release, the question heading into Thursday's session is less about the quarterly numbers in isolation and more about whether the Idesa deal confirmation and earnings tone together justify a price that has now arrived at the Street's pre-rally consensus target in a single week.
See the live data behind this article on ORTEX.
Open BRKM5 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
